Atea Pharmaceuticals Inc (AVIR) Unusual Options Activity Today

Checking AVIR unusual options activity helps you spot when traders are making outsized bets on Atea Pharmaceuticals Inc before the broader market catches on. Atea Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor AVIR unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching AVIR unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking AVIR unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and AVIR unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.

It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Catalysts rarely arrive without a footprint, and AVIR unusual options activity is often where that footprint shows up first. Our scanner tracks Atea Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at AVIR unusual options volume on the call side or chasing put sweeps, Atea Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.